BFM
PRAX icon

Boothbay Fund Management’s Praxis Precision Medicines PRAX Stock Holding History

Boothbay Fund Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-124,200
Closed -$5.14M – 1862
2024
Q2 		$5.14M Buy
+124,200
New +$5.87M 0.12% 219

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Boothbay Fund Management's PRAX Position: Q2 2026 in Review

Boothbay Fund Management increased its Praxis Precision Medicines (PRAX) stake by 2.2% in Q2 2026, buying an estimated $121K and bringing the position to 17,968 shares worth $6.02M. The position accounts for 0.08% of the portfolio, ranked #292.

Boothbay Fund Management first reported a position in PRAX in Q3 2021 and has held it in 13 quarters since. The position peaked at $6.18M in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Boothbay Fund Management held 17,968 shares of Praxis Precision Medicines worth $6.02M as of Q2 2026.
  • Boothbay Fund Management bought 381 Praxis Precision Medicines shares in Q2 2026, an estimated $121K.
  • Praxis Precision Medicines made up 0.08% of Boothbay Fund Management's portfolio in Q2 2026, its #292 holding.
  • Boothbay Fund Management first reported a position in Praxis Precision Medicines in Q3 2021 and has held it in 13 quarters since.
  • Boothbay Fund Management's Praxis Precision Medicines position peaked at $6.18M in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.